120709-59-3

Upstream product

• 123-91-1 1,4-dioxane 
• 501-53-1 benzyl chloroformate 
• 159002-17-2 N^α-Boc-α,β-diaminopropionic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 61177-01-3 2-amino-3-benzyloxycarbonylaminopropionic acid 

Downstream Products

• 693222-13-8 {2-[1-(benzyloxycarbonylamino-methyl)-3-chloro-2-oxo-propylcarbamoyl]-2-tert-butoxycarbonylamino-ethyl}-carbamic acid benzyl ester 
• 765270-50-6 (2-amino-4-chloro-3-oxo-butyl)-carbamic acid benzyl ester 
• 693222-09-2 (2-tert-butoxycarbonylamino-4-chloro-3-oxo-butyl)-carbamic acid benzyl ester 
• 501022-57-7 3,6-bis(benzyloxycarbonylaminomethyl)-5-methyl-1,2-dihydropyrazin-2-one 
• 129398-50-1 Boc-DL-Dap(Z)-D-Glu(OBzl)-NH₂ 
• 129398-52-3 (R)-4-(2-Amino-3-benzyloxycarbonylamino-propionylamino)-4-carbamoyl-butyric acid benzyl ester; compound with trifluoro-acetic acid 
• 159002-17-2 N^α-Boc-α,β-diaminopropionic acid 

Relevant academic research and scientific papers

2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

1,5-benzodiazepine derivatives

This invention relates to 1,5-benzodiazepine derivatives, which are each represented by the following formula (1): wherein R1represents a lower alkyl group, R2and R3may be the same or different and represent a hydrogen atom or a lower alkyl group, R4represents a cyclohexyl group or phenyl group, and n stands for an integer of from 1 to 3, and also to medicines containing the same. These compounds are useful as curatives or preventives for diseases in which a gastrin receptor and/or a CCK-B receptor takes part.

1,5 Benzodiazepine derivatives

1,5-Benzodiazepine derivatives represented by formula (I), salts thereof, and medicines containing the same as the active ingredient: The compounds exhibit excellent gastrin and/or CCK-B receptor antagonism and are useful as remedies for gastric ulcer and gastrointestinal movement disorder.

7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease

7-Oxabicycloheptane substituted prostaglandin analogs useful in treating thrombotic and vasopastic disease have the structural formula STR1 wherein m is 1, 2 or 3; n is 1, 2, 3 or 4; Z is --(CH2)2 --, --CH=CH-- or STR2 wherein Y is O, a single bond or vinyl, with the proviso that when n is 0, if Z is STR3 then Y cannot be O, and Z is --CH=CH--, n is 1, 2, 3 or 4; and when Y=vinyl, n=0; R is CO2 H, CO2 lower alkyl, CH2 OH, CO2 alkali metal, CONHSOR3, CONHR3a or --CH2 --5-tetrazolyl, X is O, S or NH; and where R1, R2, R3 and R3a are as defined herein.